Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Just seen this on the sky news app under the opinion sections dated the 14th of May titled ‘I got an antibody test but do they really tell us anything’
Also At the bottom of the article is a minute long video of a sky news presenter using a swab to test her daughter and clearly shows how difficult using a swab can be, definitely worth a watch if you have only heard how these things are used.
Why is it that when I do a dummy sell to get an idea off the price HL is 15 minutes behind it sometimes doesn’t give me a quote but if I do a smaller figure it will give me a price. Basically saying it would allow me to sell ‘x’ amount of shares?
Thankyou
Correct me if I’m wrong, but I also believe these tests that have recently been mentioned in the news are only to tell if you’ve had covid-19 and not if you actually have it right now, there for they wouldn’t encroach on our market anyway...still all very positive with holding a lot of news to come! Very excited to say the least!!
Remember hold onto your shares! Best bit of advice I’ve read in here so far.
Good afternoon everyone, for a complete novice could someone please explain why yesterday there was nearly 1mil more shares bought than sold but the sp dropped a little, today bought and sold are pretty much even but its rocketing??
I 100% believe in this company and have made a considerable profit for myself but will be holding these for the long run.
thanks everyone for all your informative posts
who ever made this trade yesterday is going to be kicking themselves....new to this and id like to say thankyou to everyone that has had a valuable input on this share, you guys single handedly kept me from ****ting my pants and selling!! thankyou
14-May-20
12:59:00
106.00
315,000
Sell*
106.00
107.00
333.90k
Thankyou for explaining that, makes more sense now!!
Why does this trade come up as unknown rather than the usual buy/sell? Sorry new to all this trying to learn the ropes.
Thankyou
Yourgene Health plc
("Yourgene" or the "Company")
Year-end Trading update: Revenues increase 86%
Manchester, UK - 20 April 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the year ended 31 March 2020.
Revenues for the year ended 31 March 2020 were £16.6m (2019: £8.9m), up 86% compared to the previous year, and does not include £0.4m of orders for March that fell into the new financial year due to COVID-19 transport restrictions. The revenue increase reflects organic growth of approximately 36%; 11 months contribution from Elucigene Diagnostics, acquired on 26 April 2019; and three weeks' contribution from the Company's French NIPT distribution business, acquired on 10 March 2020.
Revenues by region
The strong growth across all regional segments shown below demonstrates the Company's diversified geographic base. Despite the disruptions caused by the spread of COVID-19, our customers in Europe are continuing to operate as normal, albeit with some slight timing delays if and where there are localised staffing or logistics issues. The integration of the French distribution business is also progressing to plan.
Our core South East Asian markets have so far been very successful in containing the virus and avoiding restrictive practices which might have otherwise inhibited our business there. Travel disruption has had an impact on our launch in the US, where we do not have local teams in place yet, and whilst we are recording our first revenues in this key market, we do expect further orders to be fulfilled in the new financial year.
Regional segments
Year ended
30 March 2020
£m
Year ended
30 March 2019
£m
UK
2.0
1.2
+67%
Europe
4.1
1.8
+132%
International
10.4
5.9
+77%
Total
16.6
8.9
+86%
Revenues by product
Global sales of non-invasive prenatal testing (NIPT) products and services grew at 29% and this is whilst UK and Europe customers wait to transition to our Illumina-based IONA® test, for which we are awaiting regulatory approval during the first quarter of the new financial year. Preparations for the product launch are well advanced and will commence as soon as regulatory approval is obtained and COVID-19 restrictions permit.
During the year to 31 March 2020 we have successfully broadened our portfolio beyond NIPT with 22% of sales now derived from reproductive health products and 17% derived from the Company's rapidly growing Oncology & Research Services activities in Asia.
Product segments
Year ended
31 March 2020
£m
Year ended
31 March 2019
£m
NIPT
10.1
7.9
+29%
Reproductive Health
3.7
0.0
n/a
Oncology & Research services
2.8
1.0
+177%
Total
16.6
8.9
+86%
Whilst the impact of COVID-19 in the final quarter was a major challenge the Company still delivered a strong end to the year. Yourgene has in place robust systems to continue to operate efficiently and to provide customers with worl
“We are looking for a QC Assistant to assist in the manufacture and quality control release of Yourgene Health products. Yourgene Health produce products for a wide range of areas including #Covid19 test kits, NIPT, reproductive health, pharmacogenetics, genetic disease diagnosis and cystic fibrosis.
https://bit.ly/2UZ2Esx”